 Idiopathic pulmonary fibrosis, IPF, is a chronic and progressive lung disease characterized by scarring of the lung's air sacs. Currently, no cure exists for IPF, so researchers are looking for alternative treatments. Feroptosis has been found to play a role in the progression of IPF, suggesting that it could be a potential therapeutic target. This paper proposes the use of nanomedicines containing feroptosis inhibitors as a way to treat IPF. The authors suggest that these nanomedicines should be delivered via a pulmonary drug delivery system, PDDS, which would allow them to reach the lungs more efficiently than other routes of administration. Additionally, they discuss the challenges associated with developing such a system and how to overcome them. This article was authored by Mengqin Guo, Tingting Peng, Chuan Bin Wu, and others.